A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Respiratory Syncytial VaccineBiological: Placebo
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04851977
- Locations
- 🇦🇺
Advanced Vaccine Laboratories Pty Ltd, Melbourne, Victoria, Australia
Safety and Efficacy of BARS13 in the Elderly
Phase 2
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)Drug: PlaceboDrug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT04681833
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
🇦🇺CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath